BIOQ (Bioqual) EBITDA per Share: $0.68 (TTM As of Nov. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOQ Bioqual Inc BIOQ
54 GF Score
Price $33.00
! 4 Warning Signs
View Full Analysis

What is Bioqual EBITDA per Share?

Bioqual BIOQ 54 EBITDA per Share is $0.68 as of Nov. 2025. GuruFocus rates BIOQ with a GF Score™ of 54/100. The stock has 4 warning signs investors should review. Among 165 Medical Diagnostics & Research companies, Bioqual ranks better than 92.73% on this metric.

Bioqual's EBITDA per Share for the three months ended in Nov. 2025 was $-0.46. Its EBITDA per Share for the trailing twelve months (TTM) ended in Nov. 2025 was $0.68.

During the past 12 months, the average EBITDA per Share Growth Rate of Bioqual was -116.60% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 60.60% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 30.40% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 19.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Bioqual's EBITDA per Share or its related term are showing as below:

BIOQ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -8.8   Med: 23.4   Max: 60.6
Current: 60.6

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Bioqual was 60.60% per year. The lowest was -8.80% per year. And the median was 23.40% per year.

BIOQ's 3-Year EBITDA Growth Rate is ranked better than
92.73% of 165 companies
in the Medical Diagnostics & Research industry
Industry Median: 11 vs BIOQ: 60.60

Bioqual's EBITDA for the three months ended in Nov. 2025 was $-0.41 Mil.

During the past 12 months, the average EBITDA Growth Rate of Bioqual was -116.60% per year. During the past 3 years, the average EBITDA Growth Rate was 59.90% per year. During the past 5 years, the average EBITDA Growth Rate was 29.80% per year. During the past 10 years, the average EBITDA Growth Rate was 19.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Bioqual was 59.90% per year. The lowest was -9.60% per year. And the median was 23.00% per year.


Bioqual  (OTCPK:BIOQ) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Bioqual EBITDA per Share Related Terms


Bioqual EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Bioqual's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioqual EBITDA per Share Chart

Bioqual Annual Data
Trend May01 May03 May04 May05 May06 May07 May10 May11 May17 May18
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.63 1.64 1.66 8.04 6.81

Bioqual Quarterly Data
Aug06 Nov06 Feb07 May07 Nov09 Feb10 May10 Aug10 Nov10 Feb11 May11 Aug11 May17 May18 Aug22 Aug23 Aug24 Nov24 Aug25 Nov25
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.02 0.50 -2.04 1.13 -0.46
BIOQ
54GF Score
Bioqual Inc BIOQ
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioqual EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Bioqual's EBITDA per Share for the fiscal year that ended in May. 2018 is calculated as

EBITDA per Share(A: May. 2018 )
=EBITDA/Shares Outstanding (Diluted Average)
=6.077/0.893
=6.81

Bioqual's EBITDA per Share for the quarter that ended in Nov. 2025 is calculated as

EBITDA per Share(Q: Nov. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-0.41/0.894
=-0.46

EBITDA per Share for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of $0.68 mean?
Bioqual (BIOQ) has a EBITDA per Share of $0.68 as of Nov. 2025. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Bioqual and its competitors. According to the industry distribution chart, Bioqual ranks #12 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 7.3%.
Is Bioqual's EBITDA per Share too high?
Bioqual's current EBITDA per Share is $0.68. The Medical Diagnostics & Research industry median EBITDA per Share is 11.00. Bioqual's value of $0.68 is 93.8% below this industry median. Based on the distribution chart, Bioqual ranks #12 out of 165 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Bioqual has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Bioqual's EBITDA per Share compare to ADVB and QUCY?
According to the Medical Diagnostics & Research industry distribution chart, Bioqual ranks #12 out of 165 companies for EBITDA per Share. This places Bioqual in the top 7% of its industry — outperforming the majority of peers. The industry median EBITDA per Share is 11.00. Bioqual's value of $0.68 is 93.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Medical Diagnostics & Research company?
The median EBITDA per Share among Medical Diagnostics & Research companies is 11.00, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioqual's current EBITDA per Share of $0.68 is 93.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Bioqual and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA per Share is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioqual's current EBITDA per Share is $0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioqual stock overvalued right now?
Bioqual (BIOQ) has a current EBITDA per Share of $0.68. The current EBITDA per Share is $0.68 and 93.8% below the Medical Diagnostics & Research industry median of 11.00. Bioqual's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Bioqual (BIOQ), the current EBITDA per Share is $0.68 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioqual Business Description

Address 9620 Medical Center Drive, Suite 310, Rockville, MD, USA, 20850
Bioqual Inc is a United States-based medical research company. It is engaged in providing contract research services focused on animal models of human diseases, including AIDS, influenza, RSV infection, flavivirus infections like Zika and Dengue, malaria, hepatitis, and cancer. The company is also involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. It provides services to the federal government, universities, and the life science and pharmaceutical industries. It derives revenue from the provision of contract research services.
54GF Score

Get the complete analysis for BIOQ

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$33.00
Price